NHS-MMAF

• Description :

  NHS-MMAF is a modified MMAF extracted from patent WO2012143499, intermediat 219. MMAF is a potent tubulin polymerization inhibitor and is used as a antitumor agent[1]

• UNSPSC :

  12352005

• Target :

  Drug-Linker Conjugates for ADC; Microtubule/Tubulin

• Type :

  Reference compound

• Related Pathways :

  Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage; Cytoskeleton

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/nhs-mmaf.html

• Purity :

  97.20

• Solubility :

  DMSO : 112 mg/mL (ultrasonic)

• Smiles :

  OC([C@H](CC1=CC=CC=C1)NC([C@H](C)[C@H]([C@@]2([H])N(CCC2)C(C[C@@H](OC)[C@H]([C@@H](C)CC)N(C)C([C@H](C(C)C)NC([C@H](C(C)C)N(C)CCCCCC(ON3C(CCC3=O)=O)=O)=O)=O)=O)OC)=O)=O

• Molecular Formula :

  C49H78N6O12

• Molecular Weight :

  943.18

• References & Citations :

  [1]WO2012143499

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C (Powder, sealed storage, away from moisture and light)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [1404073-19-3]